Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioVaxys Technology ( (TSE:BIOV) ) just unveiled an announcement.
BioVaxys reported highly promising Phase 1 clinical data showing that its DPX-formulated cancer vaccines MVP-S and DPX-SurMAGE were well tolerated and induced strong systemic antigen-specific T-cell responses in patients with recurrent non-muscle invasive bladder cancer who had failed prior intravesical therapy. In a small 12-patient, two-arm trial led by Dr. Yves Fradet, more than half of MVP-S recipients and one-third of DPX-SurMAGE recipients demonstrated significant and sustained T-cell responses against survivin and MAGE-A9, with some patients remaining recurrence-free after an average two years of follow-up, underscoring the potential of BioVaxys’ DPX platform as a differentiated, durable immunotherapy approach and a possible alternative to existing bladder cancer treatments.
Spark’s Take on TSE:BIOV Stock
According to Spark, TipRanks’ AI Analyst, TSE:BIOV is a Underperform.
BioVaxys Technology faces severe financial challenges, with no revenue and reliance on external financing, which heavily impacts its overall score. Technical analysis indicates weak momentum and a bearish trend, while the negative valuation metrics highlight the risks involved. However, the company is taking steps towards financial management and exploring new market opportunities, which could improve its future prospects.
To see Spark’s full report on TSE:BIOV stock, click here.
More about BioVaxys Technology
BioVaxys Technology Corp. is a clinical-stage biotechnology company developing advanced immunotherapies in oncology, infectious disease, allergy and other immune disorders, built around its DPX antigen-delivery and immune-educating technology platform. The company’s lead candidates, including the cancer vaccines maveropepimut-S (MVP-S) and DPX-SurMAGE, target tumor-associated antigens such as survivin and MAGE-A9, with a focus on hard-to-treat cancers like non-muscle invasive bladder cancer.
Average Trading Volume: 67,757
Technical Sentiment Signal: Sell
Current Market Cap: C$6.41M
For detailed information about BIOV stock, go to TipRanks’ Stock Analysis page.